Company: Blade Therapeutics
Job title: Vice President, Clinical Research
Dr. Imperial received her MD at New York Medical College and did her residency, chief residency and Clinical Nutrition fellowship at the Harvard-NE Deaconess Hospital in Boston, followed by GI/Hepatology fellowship in San Francisco at California Pacific Medical Center, UCSF and University of Pittsburgh. She spent the first part of her academic career as a transplant hepatologist at California Pacific Medical Center, where she founded the CPMC Liver Transplant Program. After a successful seven years in San Francisco, the transplant team was invited to move to Stanford University where Dr. Imperial was full-time faculty from 1995-2014, and adjunct faculty through 2016. She was also appointed Associate Clinical Professor of Pediatrics at Stanford during that time due to her ongoing work in the Pediatric Liver Transplant Program. She became a Fellow of the American Association forthe Study of Liver Disease in 2016.
After her academic career, Dr. Imperial joined Onyx Pharmaceuticals as Director of Medical Affairs in charge of the Liver Cancer program and worked closely with Bayer Health. Subsequently, she was Senior Medical Director of Clinical Development both at FibroGen and Conatus Pharmaceuticals where she focused on liver fibrosis and treatments for advanced liver disease including chronic HBV and NASH.
She joined Blade Therapeutics early in 2019 as Vice President of Clinical Research and has been instrumental in developing Phase 2 protocols in both chronic liver disease and interstitial lung disease. Throughout her career in industry, Dr. Imperial has maintained a small outpatient practice and has been involved in the care of end stage liver disease and liver transplant patients. She continues to be active in AASLD and the Liver Forum and was Co-Moderator of the NASH Baseline Parameters for Clinical Trials Working Group, and co-author of the first Liver Forum publication focusing on NASH (Gastroenterology, 2017).
Panel Discussion: How Should we Rethink Our Approach to NASH: Collating Lessons Learned for Future Decisions 8:30 am
day: Day One